J Cardiovasc Med (Hagerstown). 2026 Aug 1;27(8):612-616. doi: 10.2459/JCM.0000000000001899. Epub 2026 Jul 31.
ABSTRACT
BACKGROUND: Despite successful transcatheter aortic valve interventions (TAVIs), a residual risk of heart failure (HF) hospitalization persists.
RESULTS: A total of 37 490 patients from Optum's de-identified Clinformatics Data Mart were included. HF diagnosis was recorded in 21 283 (56.9%) patients during a year before TAVI. One-/two-year risks for a composite of HF hospitalization and mortality were 15.6% [95% confidence interval (CI), 15.2-16.0]/25.4% (95% CI, 24.8-25.9). Post-TAVI, HF medication prescriptions remained low.
MAJOR FINDINGS: HF burden among TAVI recipients is high and HF therapies are underused. Persistent residual risks highlight the need for future clinical trials investigating a role of more aggressive medical management after TAVI.
PMID:42710009 | DOI:10.2459/JCM.0000000000001899